Patients with advanced breast cancer are being denied access to life-prolonging drug

November 18, 2019

Lisbon, Portugal: Survival for patients with the most common forms of advanced breast cancer could be substantially improved if both younger and older patients had access to a group of anti-cancer drugs called CDK4/6 inhibitors, according to experts at the Advanced Breast Cancer Fifth International Consensus Conference (ABC5) in Lisbon today (Saturday). [1]

In a session agreeing new guidelines for treating advanced breast cancer, they said there was now enough evidence that this class of medicines helps patients live longer and with the same or better quality of life. However, they said the medicines were not being offered to the majority of patients who could benefit.

The experts also highlighted that difficulties with access to opioid pain relief around the world, including a lack of supply in poorer countries and a backlash against opioid addiction in the USA, are leading to breast cancer patients suffering unnecessarily and dying in pain.

A key aim of the Advanced Breast Cancer Conferences and the ABC Global Alliance [2] is to double survival among patients with the disease by 2025. Chair of the ABC5 Conference, Professor Fatima Cardoso, Director of the Breast Unit of the Champalimaud Cancer Centre in Lisbon, Portugal, said: "We now have a family of drugs, CDK4/6 inhibitors, that can substantially prolong life in the most common subtype of breast cancer.

"These drugs bring us much closer to our aim of doubling the time patients with advanced breast cancer live without their disease progressing, but we can only achieve that if they are available to everyone who needs them."

Around 70% of advanced breast cancers are oestrogen receptor positive (ER+) and HER2 negative - also called hormone dependent cancers. ER+ cancers are driven by the hormone oestrogen.

"For these cancers, CDK4/6 inhibitors should be the standard of care, both for younger, pre-menopausal and older, menopausal women, as well as men with advanced breast cancer," said Prof Cardoso. "However, the major problem is the cost of these medicines and, at present, only a small proportion of patients around the world are being treated with them. The same occurs with anti-HER2 therapies, which can prolong survival substantially for another subtype of advanced breast cancer - HER2 positive breast cancer.

"There is unequal access to these medicines not only between countries, but within countries as well, and between pre- and post-menopausal women. Our panel of world experts on the treatment of breast cancer agrees that CDK4/6 inhibitors should be make available to every patient who could benefit from them, not just a small percentage."

The experts also called on policy-makers worldwide to ensure that fears about the abuse of opioids should not limit cancer patients' access to adequate pain control.

In the new guidelines, they state: "The advanced breast cancer (ABC) community is aware of limitations that are being imposed worldwide, as a consequence of the perceived abuse of opioids in certain areas of the world. The ABC community is united in insisting that cancer patients should not have restrictions placed that will limit their access to adequate pain control."

Professor Eric Winer, Director of the Breast Cancer Program at Dana-Farber and the Dana-Farber/Harvard Cancer Center, Boston, USA, and co-chair of the conference, said: "Patients with advanced breast cancer can suffer pain and other symptoms, particularly towards the end of their lives. We need to ensure that appropriate pain medications and other symptom interventions are available to them.

"We acknowledge that the misuse of opioids is a big problem, particularly in the United States, but we need to make sure that in trying to deal with this problem we do not interfere with pain management in cancer patients. In addition, in some low- and middle-income countries, such as some in Africa, there are problems with patients being able to access any form of pain relief, and this needs to be addressed urgently."

The panel of experts also called for further research into the use of cannabis for managing symptoms and pain in patients with advanced breast cancer. However, they stressed that it should never replace existing medicines that have been proven to work, such as morphine.

"The panel encourages research on the potential role of cannabis to assist in pain and symptom control but strongly stresses that it cannot replace proven medicines, such as morphine, for adequate pain control," say the experts in their new guidelines.

These issues were among several addressed by 1,500 experts and patients from approximately 90 countries around the world at the conference as they agreed new and modified guidelines for the treatment and management of all types of advanced breast cancer. The new guidelines will be published in Breast and Annals of Oncology in 2020.

There are no reliable figures for the numbers of women (and men) living with advanced breast cancer. However, there are over two million new cases of breast cancer a year in the world and 0.6 million deaths. About 5-10% of cases are either locally advanced or have spread to other parts of the body (metastasised) at diagnosis, and these figures reach almost 80% in developing countries. About a third of all early breast cancer cases will become metastatic even with the best care, and the average overall survival for these patients is around three years.

European School of Oncology

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to